@article{3365d47716864688ad4a46299a112521,
title = "Combination of lipitor and celebrex inhibits prostate cancer VCaP cells in vitro and in vivo",
abstract = "Background/Aim: Lipitor is a cholesterollowering drug and Celebrex is a Cyclooxygenase-2 inhibitor. We investigated the effects of Lipitor and Celebrex on human prostate cancer VCaP cells cultured in vitro and grown as orthotopic xenograft tumors in SCID mice. Materials and Methods: Apoptosis was measured by morphological assessment and caspase-3 assay. Nuclear factor-kappa B (NF-κB) activation was determined by luciferase reporter assay. B-cell lymphoma-2 (Bcl2) was measured by western blotting and immunohistochemistry. Orthotopic prostate tumors were monitored by the IVIS imaging system. Results: the combination of Lipitor and Celebrex had stronger effects on the growth and apoptosis of VCaP cells than did either drug alone. The combination more potently inhibited activation of NFκB and expression of Bcl2 than either drug alone. The growth of orthotopic VCaP prostate tumors was strongly inhibited by treatment with the drug combination. Conclusion: Administration of Lipitor and Celebrex in combination may be an effective strategy for inhibiting the growth of prostate cancer.",
keywords = "NFκB, NSAIDs, Orthotopic, Prostate cancer, Statin",
author = "Huarong Huang and Cui, \{Xiao Xing\} and Shaohua Chen and Susan Goodin and Yue Liu and Yan He and Dongli Li and Hong Wang and \{Van Doren\}, Jeremiah and Dipaola, \{Robert S.\} and Conney, \{Allan H.\} and Xi Zheng",
year = "2014",
month = jul,
day = "1",
language = "English",
volume = "34",
pages = "3357--3363",
number = "7",
}
